BNP Paribas Développement — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.
BiotechHealthtech
Marc Lemonnier(Chief Executive Officer)inRienk Pypstra(Chief Medical Officer)Gordon Waldron(Chief Financial Officer)inMagdalena Zalacain(Chief Scientific Officer)in
Co-investorsAMR Action FundIRDI SORIDEC Gestion
Lactips produces natural, biobased polymers derived from protein that are biodegradable and water-soluble, addressing microplastic pollution across industrial applications.
Circular EconomyCleantechNew MaterialsSaint-Paul-en-Jarez, FR
Co-investorsDiamond Edge VenturesBlue Ocean Capital GroupBpifranceDemeterGO CapitalSWEN Capital Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.